[1]
Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol 2014; 5: 352.
[2]
Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21(1): 335-76.
[3]
Janeway CA. Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press 1989; pp. 1-13.
[4]
Huang L-Y, DuMontelle JL, Zolodz M, Deora A, Mozier NM, Golding B. Use of toll-like receptor assays to detect and identify microbial contaminants in biological products. J Clin Microbiol 2009; 47(11): 3427-34.
[5]
Lee MS, Kim Y-J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007; 76: 447-80.
[6]
Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O’neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat Rev Rheumatol 2016; 12(6): 344-57.
[7]
De Jager PL, Franchimont D, Waliszewska A, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8(5): 387-97.
[8]
Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol 2014; 47(2): 136-47.
[9]
Sidiropoulos P, Hatemi G, Song I-H, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008; 47(3): 355-61.
[10]
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis 2013; 5(1): 45-54.
[11]
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013; 15(3): S2.
[12]
Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel FA. An update on the treatment of the cutaneous manifestations of systemic sclerosis: The dermatologist’s point of view. J Clin Aesthet Dermatol 2012; 5(7): 33-43.
[13]
Østensen M, Villiger P. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001; 10(3): 135-9.
[14]
Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57(2): 181-7.
[15]
Page TH, Turner JJ, Brown AC, et al. Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol 2010; 185(6): 3694-701.
[16]
Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 2015; 37(6): 535-40.
[17]
Mirshafiey A, Hosseini S, Afraei S, Rastkari N. T Zavareh F, Azizi G. Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in rat model. Curr Drug Discov Technol 2016; 13(1): 25-33.
[18]
Nazeri S, Khadem Azarian S, Fattahi MJ, et al. Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacol Immunotoxicol 2017; 39(2): 59-65.
[19]
Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of beta-D-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 2015; 37(6): 535-40.
[20]
Afraei S, Azizi G, Zargar SJ, Sedaghat R, Mirshafiey A. New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurol Belg 2015; 115(3): 259-66.
[21]
Mirshafiey A, Hosseini S, Afraei S, Rastkari N, Zavareh FT, Azizi G. Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in Rat model. Curr Drug Discov Technol 2016; 13(1): 25-33.
[22]
Nazeri S, Khadem Azarian S, Fattahi MJ, et al. Preclinical and pharmacotoxicology evaluation of alpha-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacol Immunotoxicol 2017; 39(2): 59-65.
[23]
Arjomand Fard N, Tabrizian N, Mirzaei R, et al. Efficacy and safety of G2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Iran J Public Health 2017; 46(2): 216-21.
[24]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods 2001; 25(4): 402-8.
[25]
Sidiropoulos PI, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008; 47(3): 355-61.
[26]
Afraei S, Azizi G, Zargar SJ, Sedaghat R, Mirshafiey A. New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurol Belg 2015; 115(3): 259-66.
[27]
Hajivalili M, Pourgholi F, Majidi J, et al. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Mol Cell Biol 2016; 62(4): 1-5.
[28]
Mortazavi JSS, Yousefi M, Sadat NS, Motamed N, Tofighi ZF, Mirshafiey A. Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line. Eur J Inflamm 2016; 14(2): 86-92.
[29]
Sharifi L, Mohsenzadegan M, Aghamohammadi A, et al. Immunomodulatory effect of G2013 (a-L-Guluronic acid) on theTLR2 and TLR4 in human mononuclear cells. Curr Drug Discov Technol 2018. [Epub ahead of print].
[30]
Sharifi L, Mohsenzadegan M, Rezaei N, et al. Immunomodulation of TLR2 and TLR4 by G2013 (alpha-L-guluronic acid) in CVID patients. Int J Pediatr 2017; 5(7): 5327-37.
